Identification of dysregulated microRNA expression and their potential role in the antiproliferative effect of the essential oils from four different Lippia species against the CT26.WT colon tumor cell line  by Gomide, Mayna et al.
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a  b  s  t  r  a  c  t
In spite  of  advances  in  colorectal  cancer  treatments,  approximately  1.4  million  new  global  cases  are  esti-
mated  for  2015.  In this  sense,  Brazilian  plant  diversity  offers  a  multiplicity  of essential  oils as  prospective
novel  anticancer  compounds.  This  study  aimed  to evaluate  the  antiproliferative  effect  of  the essential
oils  from  four Lippia  species  in  CT26.WT  colon  tumor  cells,  as  a measurement  of cell  cycle  phase  dis-
tribution  and  microRNA  expression.  CT26.WT  showed  cell  cycle  arrest  at G2/M  phase  after  treatment
with  100  g/ml  of Lippia  alba  (Mill.)  N.E.Br.  ex Britton  & P.  Wilson,  Lippia  sidoides  Cham.,  and  Lippia
lacunosa  Mart.  & Schauer,  Verbenaceae,  essential  oils  and,  at the  same  concentration,  Lippia  rotundifoliaT26.WT
ippia essential oil
icroRNA
ell cycle phases
Cham.  essential  oil caused  an augment  of G0/G1  phase.  The  miRNA  expression  proﬁling  shows  change
of  expression  in  key  oncogenic  miRNAs  genes  after  treatment.  Our ﬁndings  suggest  growth  inhibition
mechanisms  for all  four  essential  oils  on  CT26.WT  cells  involving  direct  or indirect  interference  on  cell
cycle arrest  and/or  oncogenic  miRNAs  expression.
©  2016  Sociedade  Brasileira  de Farmacognosia.  Published  by Elsevier  Editora  Ltda.  This  is  an open
he  CCaccess  article  under  t
ntroduction
According to the International Agency for Research on Cancer,
olorectal cancer (CRC) was the third most common cancer in men
nd the second most common in women worldwide in 2012 (Ferlay
t al., 2015). Approximately 1.4 million new global CRC cases and
ore than 750,000 deaths were projected for 2015 (Ferlay et al.,
015). Colorectal cancer treatments involve the standard tech-
iques of surgery, radiation and chemotherapy and a few derivative
rocedures like cryosurgery, radiofrequency ablation or targeted
herapy. Despite technological advances, CRC demonstrates great
esistance and resilience against therapy. Approximately 40% of all
atients treated for local CRC will have recurrence (Siegel et al.,
012) and thus, the search for new anticancer agents remains
ssential.
∗ Corresponding author.
E-mails: mayna.gomide@ufjf.edu.br (M.  Gomide), cintiacoelhom@unb.br
C. Marques Coelho).
http://dx.doi.org/10.1016/j.bjp.2016.04.003
102-695X/© 2016 Sociedade Brasileira de Farmacognosia. Published by Elsevier Edit
reativecommons.org/licenses/by-nc-nd/4.0/). BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Plant compounds feature important sources of therapeutic com-
pounds for cancer treatment. Countries with rich ﬂora biodiversity
as Brazil have a wide range of plant species and there has been
a global effort to prospect for biomolecules with pharmacological
properties in these regions. Among these, monoterpenes have been
suggested as a relevant class of agents that are found in several
plant species, including species of the Lippia genus, whose phar-
macological properties have been related to secondary metabolites,
speciﬁcally to their essential oils (Pascual et al., 2001). Among the
best studied Lippia species are L. alba (Mill.) N.E.Br. ex Britton & P.
Wilson, and L. sidoides Cham., and for both of them previous stud-
ies reported antioxidant activity indicating that these plants might
be potential targets to search for antitumorogenic biomolecules
(Ramos et al., 2003; Monteiro et al., 2007). Recently, our group
investigated the antiproliferative effect of ﬁve Lippia species on
tumor cells, as determined by MTT  assay. The results of this study
demonstrated that L. sidoides and L. salviifolia essential oils had
an antiproliferative effect on CT26.WT colon tumor cells (Gomide
et al., 2013). Monoterpenes like geraniol found in vegetal essential
oils had already been showed to reduce the growth of leukemia
ora Ltda. This is an open access article under the CC BY-NC-ND license (http://
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nd melanoma cells (Shoff et al., 1991). Others have also demon-
trated that synthetic geraniol is effective in vitro and in vivo against
 variety of cancer types, including hepatoma, pancreatic and even
olon cancer, which is highly resistant to chemotherapy (Yu et al.,
995; Burke et al., 1997; Carnesecchi et al., 2001, 2002; Duncan
t al., 2004; Ong et al., 2006; Wiseman et al., 2007). The monoter-
ene limonene is another that has exerted antitumor activity,
peciﬁcally against breast, skin, liver, lung and stomach cancers
n rodents (Elegbede et al., 1986; Wattenberg and Coccia, 1991;
rowell and Gould, 1994; Mills et al., 1995; Kawamori et al., 1996;
rowell, 1999). Additionally, anti-tumor activity has been reported
o monoterpenes like carvone, carveol, mentol and perillyl alcohol
He et al., 1997).
The molecular driving forces of CRC can be categorized into
enomic instability, genomic modiﬁcations and epigenetic alter-
tions (Kanthan et al., 2012). More recently, several studies have
bserved that an imbalance in miRNA regulating cell cycle onco-
enes could also be linked to cancer development. In CRC, studies
ave demonstrated an association of aberrant miRNA expression
nd cancer development where some miRNA have been reported
o be consistently dysregulated in this disease (Huang et al., 2010).
The aim of the present study was to evaluate the antiprolifera-
ive effect of the essential oils extracted from four different Lippia
pecies in CT26.WT colon tumor cells as a measurement of cell cycle
hase distribution and miRNAs expression.
aterials and methods
lant material
Fresh leaves were collected from Lippia alba (Mill.) N.E.Br. ex
ritton & P. Wilson, L. sidoides Cham., L. rotundifolia Cham. and L.
acunosa Mart. & Schauer, Verbenaceae, at the Experimental Station
ocated on the campus of the Federal University of Juiz de Fora,
uiz de Fora, Brazil (21◦46′48.4′′S 43◦22′24.4′′ W).  Each one of the
ippia species was collected from November to December 2010.
he voucher specimens of the Lippia species evaluated in this study
re deposited at the Herbarium of the Botany Department from
he Federal University of Juiz de Fora and the voucher specimens
umbers are: L. alba: 48374, L. sidoides: 49007, L. rotundifolia: 31376
nd L. lacunosa: 51920.
xtraction of essential oils
The essential oils from leaves of the Lippia species were obtained
y hydrodistillation in a Clevenger-type apparatus for 2 h. The oils
ere weighed and aliquots of 5 mg  of each one of them were stored
t −80 ◦C in sealed vials covered with aluminum foil until use. For
ach one of the assays described one aliquot was thawed and dis-
olved in 4% dimethyl sulfoxide – DMSO (Sigma, St. Louis, MO, USA)
nd puriﬁed water making up a working solution of 1 mg/ml.
as chromatography/mass spectrometry analysis
The chemical composition of the essential oil of each Lip-
ia specie was determined by gas chromatography coupled
o mass spectrometry performed on a Shimadzu QP5050A
C/MS instrument, equipped with a PTE-5 Supelco column
30 m × 0.25 mm × 0.25 m),  as performed by Gomide et al. (2013).
etention indexes (RI) were calculated from retention times gen-
rated from the analysis of each oil in comparison with a standard
-alkanes solution, C8-C20, and used to determine the components
f each one of the essential oils, according to Adams (1995). The
mount of compounds was determined by peaks area integration
f the spectra.rmacognosia 26 (2016) 627–633
Cell lines and culture condition
Mouse colon carcinoma CT26.WT cells were obtained from
ATCC (CRL-2638) and were grown at 37 ◦C with 5% CO2 in RPMI
1640 medium pH 7.4 (Cultilab, Campinas, SP, Brazil) supplemented
with 10% fetal bovine serum (FBS), 0.1 mg/ml  ampicillin, 0.1 mg/ml
kanamycin, 0.005 mg/ml amphotericin, 0.2% NaHCO3 and 0.2%
HEPES (Sigma, St. Louis, MO,  USA).
Cell cycle analysis
CT26.WT cells were seeded onto 24-well plates at a density of
2 × 104 cells/well in RPMI supplemented with 10% FBS. After the
cells visibly reached around 50% conﬂuence they were exposed
for 12 or 24 h with RPMI supplemented with 10% FBS contain-
ing the working solution with the essential oils of the four Lippia
species at the concentrations of 10, 50 and 100 g/ml. The nega-
tive control samples contained 0.4% DMSO, which is equivalent to
the percentage found in the highest concentration evaluated. Then,
the cells were collected and resuspended in 300 l of HFS solution
(0.05% propidium iodide, 1% sodium citrate and 0.5% Triton X-100)
(Sigma, St. Louis, MO,  USA). Cells were incubated for 2 h at 4 ◦C.
The DNA content of the stained cells was  analyzed using FACScan
and CellQuest programs (BD Bioscience, San Jose, CA, USA). The his-
tograms showing cell cycle phase distributions in G0/G1, S, G2/M
and sub-G1 cells (used as measure of dead cells) were analyzed
using FlowJo version 7.6.4 (Treestar, Inc., San Carlos, CA). All assays
were performed at least three times, and at least 15,000 events
per sample were analyzed. To verify the existence of statistical dif-
ferences among the samples ANOVA followed by Bonferroni test
was performed. Differences bellow 0.05 (p < 0.05) were considered
signiﬁcant.
MicroRNA analysis
CT26.WT cells were seeded in three different 25 cm2 ﬂasks each
one at a density of 2 × 104 cells/well in RPMI supplemented with
10% FBS. After the cells visibly reached around 50% conﬂuence they
were treated with RPMI supplemented with 10% FBS containing the
essential oil of L. alba, L. rotundifolia, L. sidoides or L. lacunosa at a
ﬁnal concentration of 100 g/ml. Cells were incubated for a period
of 12 h.
Subsequently, for the microRNA analysis, the CT26.WT cells
were submerged in RNAlater (Invitrogen, Carlsbad, CA, USA) for
24 h at 4 ◦C, and transferred to −80 ◦C. MicroRNA was  isolated
using mirVana miRNA isolation kit (Applied Biosystems, Foster City,
CA, USA), according to manufacturer’s directions. Total RNA was
quantiﬁed by NanoDrop ND-100 Spectrophotometer (NanoDrop
Technologies, Wilmington, DE, USA) and the extraction quality
was evaluated by Agilent Small RNA kit in Agilent 2100 Bioana-
lyzer (Agilent Technologies, Santa Clara, CA, USA). Cancer MicroRNA
qPCR array with Quantimir kit, a panel of 95 cancer-related microR-
NAs (System Biosciences, Mountain View, CA, USA), was  used to
examine miRNA differential expression on the two pools formed
by each essential oil-treated and untreated (negative control)
CT26.WT cells collected from three independent 25 cm2 ﬂasks. The
miRNAs were tagged and reverse transcribed using QuantiMir-
cDNA technology. The miRNA proﬁling was performed according
to the manufacturer’s instructions. Forward primers used in this
study were designed to be the exact sequences of the miRNA, and
are listed in the miRBase database (http://www.mirbase.org). Real-
time PCR was performed using standard run conditions (40 cycles,
60 ◦C anneal/extension) on a ABI Prism 7300 Sequence Detection
Systems (Applied Biosystems, Foster City, CA, USA), according to
the manufacturer’s directions. Samples were normalized to U6
transcript and analyzed using the REST 384 software by pair-wise
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xed reallocation randomization test (Pfafﬂ et al., 2002) and Ct
ethod (Livak and Schmittgen, 2001). Relative expression values
re shown as mean ± standard error (SEM) and differences bellow
.05 (p < 0.05) were considered signiﬁcant.
esults and discussion
omposition of the essential oils obtained from four Lippia species
Since previous studies have demonstrated that the quan-
ity of the main components of the essential oils obtained
rom Lippia species varies according to the sampling period, gas
hromatography–mass spectrometry analysis (GC–MS) was per-
ormed to quantify each oil composition. The most concentrated
ompounds (above 6% of total composition) were identiﬁed and
re shown in Table 1. A total of nine main compounds were found
or all species. In L. alba oil (Alb), geranial and citral predomi-
ate. For L. sidoides oil (Sid), thymol and o-cymene were the most
oncentrated. The major constituent of L. rotundifolia essential
il (Rot) was -myrcene and ﬁnally, -myrcene and myrcenone
ere the most abundant in L. lacunosa oil (Lac). This data agrees
ith previous results from Gomide et al. (2013), and the observed
hemotypes validate the identities of the Lippia species used in this
tudy.
he antiproliferative effect of essential oils from Lippia species as
etermined by the distribution of CT26.WT colon tumor cell cycle
hases
Several studies have shown that terpenes present chemo-
reventive and therapeutics properties against human cancers
Kinghorn et al., 2003). Among the terpenes, the class of monoter-
enes has emerged as an advantageous agent to be used as an
nticancer drug for treatment of tumors that are resistant to
hemotherapy and to minimize the side effects of current treat-
ents (Shoff et al., 1991; Yu et al., 1995; Burke et al., 1997; He
t al., 1997; Crowell et al., 1999; Duncan et al., 2004; Wiseman et al.,
007; Paduch et al., 2007). Several monoterpenes are identiﬁed in
ippia species Brazil being one of the largest centers of diversity of
his genus, comprising 70–75% of all known species.
A previous study showed potent antiproliferative effects in
T26.WT cells treated with Lippia essential oils (Gomide et al.,
013). In this study, CT26.WT cells were treated for 12 and 24 h
ith the essential oils extracted from L. alba, L. sidoides, L. rotundi-
olia and L. lacunosa. It was observed that all four Lippia essential
ils affected the CT26.WT cell line by inducing cell cycle arrests
ither in G0/G1 or in G2/M phases. The representative histograms
f the cell cycle phase distribution of CT26.WT cells are shown in
ig. 1. Table 2 presents the percentages of sub-G1, G0/G1, S and
able 1
ercentage chemical composition of the majority compounds of the essential oils extracte
y  gas-chromatography followed by mass spectrometry.
Compounds RIa L. alba 
-Pinene 980 
-Myrcene 991 
-Phellandrene 1005 
o-Cymene 1022 
Limonene 1031 22.43 
Myrcenone 1148 
Citral  1240 20.54
Geranial 1270 29.24
Thymol 1290 
Total 72.21 
Number of retained compounds selected 7 
a RI – retention index.rmacognosia 26 (2016) 627–633 629
G2/M CT26.WT treated cells as measured by ﬂow cytometry after
PI staining.
At 50 and 100 g/ml, results show that treatment with Alb lead
to a signiﬁcant increase of G2/M phase after 12 and 24 h. Decreasing
the concentrations to 10 g/ml still shows an increase of G0/G1
phase cells for the same times (Table 2 and Fig. 1). In agreement with
our results, the antiproliferative effect of geranial, the major com-
pound of Alb (Table 1), had already been demonstrated. Carnesecchi
et al. (2001) and Wiseman et al. (2007) observed geraniol (its oxi-
dize form is geranial) cell cycle arresting effects. The ﬁrst reported
geraniol affected progression through the S phase of the cell cycle
on colon cancer cells, while the second reported a G0/G1 cell cycle
arrest on pancreatic cancer cells. In addition, Wiseman et al. (2007)
reported a role for p21Cip1 and p27Kip1 as mediators of G0/G1
cell cycle arrest in pancreatic adenocarcinoma, and reduced lev-
els of expression of cyclins A, B1 and the CDK2. In agreement with
these previous studies, ours results also indicated that the antipro-
liferative effects of Alb might relate to its ability to affect the cell
cycle, speciﬁcally at G2/M phase. Similar results were observed by
Chaouki et al., 2009 when MCF-7 breast cancer cells were treated
for 48 and 72 h with citral, another major compound found in Alb
(Table 1).
Sid also affected CT26.WT cell cycle. Treatment with 100 g/ml
showed an increased percentage of G2/M phase and decreased S
phase cells after 12 h, while an increase in G0/G1 was observed after
24 h. The antiproliferative effect of thymol, the major compound
of Sid, had been previously demonstrated. Recently, Jaafari et al.
(2012) and Deb et al. (2011) obtained cell cycle arrest at sub G0/G1
after thymol treatment in leukemic cells.
The Rot caused an increase of CT26.WT cells on G0/G1 phase
at 50 and 100 g/ml after 12 and 24 h of treatment (Table 2 and
Fig. 1). Treatment with 50 and 100 g/ml of Lac lead to a G2/M phase
increase after 12 and 24 h as well as a considerable decrease in S
phase. At 100 g/ml there was  also an increase in G0/G1 phase after
24 h of treatment (Table 2 and Fig. 1). Abdallah and Ezzat (2011)
showed that the essential oil extracted from Pituranthos tortuo-
sus, which contains -myrcene (major compound of Rot and Lac)
showed cytotoxicity against colon, liver and breast cancer cell lines.
There were very few studies reporting effects of other identiﬁed
compounds from those Lippia oils.
Identiﬁcation of differential expression of miRNAs in Lippia
essential oil CT26.WT treated cells
Several studies show that miRNAs are master regulators of cell
cycle genes in different cancer and therefore, we  decided to inves-
tigate if miRNAs dysregulation were involved in the observed cell
cycle interference caused by essential oils from Lippia species.
To identify differential expression patterns of miRNAs in treated
d from leaves of Lippia alba, L. sidoides, L. rotundifolia and L. lacunosa, as determined
L. sidoides L. rotundifolia L. lacunosa
16.30
52.39 53.52
13.27
30.08
10.94
25.41
38.42
68.50 92.90 78.93
8 5 4
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Fig. 1. Representative histograms of the cell cycle phase distribution of CT26.WT cells after 12 and 24 h treatment with different concentrations of the essential oils extracted
f nt of t
c  in th
a
C
ﬁ
t
N
s
0
a
w
srom  Lippia alba (A), L. sidoides (B), L. rotundifolia (C), and L. lacunosa (D). DNA conte
ontrol  samples contained 0.4% DMSO, which is equivalent to the percentage found
nd  at least 15,000 events per sample were analyzed.
T26.WT cells we used real-time PCR-based miRNA expression pro-
ling array with a panel of 95 cancer-related miRNAs and an U6
ranscript to normalize signal. Table 3 shows the proportion of miR-
As from CT26.WT cells treated with the essential oils from Lippia
pecies that showed differential expression from cells treated with
.4% dimethyl sulfoxide (DMSO). The results showed that 27.36% of
nalyzed microRNAs were dysregulated on CT26.WT cells treated
ith Alb and Lac and 36.84% on cells treated with Sid and Rot.
Fig. 2 shows a heatmap comparing different miRNAs expres-
ion after CT26.WT cells treatment with Lippia oils. Some geneshe stained cells was analyzed using FACScan and CellQuest program. The negative
e highest concentration evaluated. All assays were performed at least three times,
responded as up or downregulated depending on the essential oil
type, but were dysregulated by all four types (miR-142-3p, miR-15b
and miR-202), three (miR-22, miR-149, miR-185, miR-21, miR-191,
miR-192, miR-181a, miR-132 and miR-296) or at least by one of the
oils as shown in Fig. 2. Monzo et al. (2008) and Chen et al. (2009)
reported that miR-142-3p and miR-15b were up-regulated in colo-
rectal cancer. Our results show growth inhibition correlated to
miR-15b downregulation (in 3 of 4 oils), while miR142-3p expres-
sion increased. Ng et al. (2009a, b) identiﬁed miR-202 upregulation
in colorectal cancer patient plasma, which was  also observed after
M. Gomide et al. / Revista Brasileira de Farmacognosia 26 (2016) 627–633 631
Table  2
Percentages of sub-G1, G0/G1, S and G2/M of CT26.WT cells after 12 and 24 h treatment with the essential oils extracted from Lippia alba, L. sidoides, L. rotundifolia and L.
lacunosa,  as determined by ﬂow cytometry after PI staining. The negative control samples contained 0.4% DMSO, which is equivalent to the percentage found in the highest
concentration evaluated. All assays were performed at least three times, and at least 15,000 events per sample were analyzed. Statistical differences were determined with
ANOVA  followed by Bonferroni test (p < 0.05).
Essential oil
(solutions)
sub-G1 G0/G1 S G2/M
12 h 24 h 12 h 24 h 12 h 24 h 12 h 24 h
Lippia alba
Negative control
<4 <5
25.65 ± 1.58a 27.37 ± 1.30a 40.34 ± 2.82a 39.38 ± 1.38a 24.25 ± 4.03a 23.46 ± 1.56a
10 g/ml 31.12 ± 2.04b 32.35 ± 0.75b 39.91 ± 0.96a 35.29 ± 1.20a 17.96 ± 0.83b 23.11 ± 0.34a
50 g/ml 23.69 ± 0.1a 23.07 ± 0.82c 20.53 ± 1.40b 17.31 ± 2.35b 41.89 ± 0.87c 45.31 ± 2.75b
100 g/ml 21.03 ± 0.61a 21.26 ± 1.17c 30.98 ± 2.50c 27.33 ± 2.27c 32.40 ± 2.34d 39.03 ± 1.32c
Lippia sidoides
Negative control
<4 <2
28.59 ± 3.44a 29.62 ± 2.00a 38.35 ± 3.32a 39.12 ± 2.48a 18.81 ± 3.93a 18.32 ± 1.40a
10 g/ml 26.82 ± 3.18a 33.82 ± 1.50ab 35.50 ± 3.35a 34.30 ± 1.91ab 18.86 ± 1.69a 19.52 ± 1.77a
50 g/ml 27.84 ± 1.69a 31.35 ± 2.84a 25.98 ± 2.32b 37.04 ± 0.90a 26.15 ± 1.38ab 18.93 ± 1.59a
100 g/ml 23.64 ± 1.76a 38.17 ± 1.92b 19.14 ± 2.66c 30.31 ± 1.15bc 33.25 ± 5.88b 21.23 ± 1.88a
Lippia rotundifolia
Negative control
<3 <1
29.76 ± 1.87a 36.55 ± 0.47a 38.75 ± 2.44a 29.60 ± 1.17a 15.57 ± 2.36a 20.46 ± 1.19a
10 g/ml 33.77 ± 2.74a,b 37.90 ± 1.80a,c 35.54 ± 2.33ab 28.04 ± 1.58ab 15.93 ± 2.48a 20.98 ± 2.00a
50 g/ml 36.01 ± 1.28b 40.99 ± 1.79bc 33.59 ± 1.26b 24.53 ± 0.42b 15.28 ± 3.06a 20.86 ± 1.91a
100 g/ml 41.65 ± 2.11c 38.30 ± 0.80ac 26.01 ± 1.81c 24.71 ± 0.60ab 16.02 ± 1.35a 21.09 ± 1.77a
Lippia lacunosa
Negative control
<5 <6
33.49 ± 1.51a 28.27 ± 3.27a 35.30 ± 1.99a 34.75 ± 2.11a 17.79 ± 1.34a 26.27 ± 2.53ab
10 g/ml 33.32 ± 5.53a 32.78 ± 0.87a 24.49 ± 6.19b,d 30.86 ± 0.54b 19.63 ± 1.52a 23.25 ± 1.49a
50 g/ml 19.51 ± 3.21b 19.53 ± 5.35b 9.12 ± 0.44c 20.82 ± 1.00c 33.38 ± 1.76b 29.87 ± 2.32bc
100 g/ml 35.99 ± 2.10a 48.93 ± 1.84c 15.39 ± 7.05cd 4.98 ± 1.93d 33.86 ± 6.82b 34.98 ± 2.70c
The values represent the average of at least three replicates ± SD.
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Table 3
Total microRNAs differentially expressed after CT26.WT cell line treated with Lippia
essential oils.
miRNA L. alba L. sidoides L. rotundifolia L. lacunosa
Total 59 59 57 59
Signiﬁcants (p < 0.05) 26 35 35 26,b,c,d Different letters indicate signiﬁcant statistical differences in each cell cycle ph
reatment with Lippia essential oils. Data indicates Alb, Rot and Sid
reatment correlates to reversed miR-15b expression in CT26.WT
olon cancer cell line.
Reversion of expression was observed for miR-92, miR-93, miR-
35b, miR-155, miR-191, miR-181a and miR-186 genes which were
reviously found to be upregulated in colon cancer (Volinia et al.,
006; Monzo et al., 2008; Schepeler et al., 2008; Arndt et al., 2009;
arver et al., 2009; Earle et al., 2010; Huang et al., 2010) and were
ownregulated in CT26.WT cells after treatment with Alb, Sid and
ot (Fig. 2). In contrast, miR-143 appeared upregulated on CT26.WT
ells treated with Alb, Rot and Lac (Fig. 2), but has been shown to be
onsistently downregulated in colorectal cancer (Chen et al., 2009;
ulda et al., 2010). Chen et al. (2009) showed that miR-143 acts as a
umor suppressor by inhibiting the KRAS oncogene translation. Alb,
ot and Lac seem to increase expression of miR-143 which could
ossibly cause a recovery of KRAS tumor suppressor role.
In this study, miR-192 gene was upregulated on CT26.WT cells
xposed to Alb and Lac and downregulated by Rot (Fig. 2). Chen
t al. (2009) and Earle et al. (2010) demonstrated that miR-192
as downregulated in colorectal cancer. These results indicate that
lb and Lac might be reverting expression of miR-192 in this type
f cancer. Braun et al. (2008) also demonstrated that miR-192 is
apable of suppressing carcinogenesis by increasing the level of a
1 cell cycle inhibitor p21, leading to cell cycle arrest in G1 phase
nd in G2/M phase in HCT116 human colorectal cancer cell line.
n agreement, cell cycle arrest at these phases was  observed on
T26.WT cells treated with Alb and Lac (Table 2 and Fig. 1). Expres-
ion of miR-222 was decreased in CT26.WT cells exposed to Alb, Sid
nd Rot (Fig. 2). Visone et al. (2007) showed that the expression of
iR-222 together with miR-221 in human thyroid carcinoma cell
ine induced cell cycle progression to the S phase and reduced the
xpression level of the G1 cell cycle inhibitor p27KIP1.A few miRNA genes showed reversed expression after treatment
xclusively with one of the four Lippia essential oils. The miR-
As miR-196a, miR-214, miR-149 and miR-30b were shown to be
ownregulated in colorectal cancer (Monzo et al., 2008; SchepelerUpregulated 8 13 12 23
Downregulated 18 22 23 3
et al., 2008; Chen et al., 2009; Earle et al., 2010) and our results
demonstrated that these miRNA were upregulated after CT26.WT
cells were treated with Lac (Fig. 2). On the contrary, miR-17-5p
and miR-17-3p were downregulated on CT26.WT cells by Alb and
Lac essential oils, respectively (Fig. 2). Bandres et al. (2006) and
Volinia et al. (2006) observed miR-17-5p upregulation in colorec-
tal cancer tissue. Monzo et al. (2008) reported that this miRNA is
a critical member of a functional group involved in regulating the
expression of E2F1, an upstream regulator of TP53 in colorectal
cancer cells. They also showed that cells transfected with anti-
miR-17-5p, had an increased E2F1 expression, reducing cell growth
in a dose dependent manner. In another transfection experiment,
Kanaan et al. (2012) transfected miR-17 in colon cancer lines HT-29
and HCT-116 and showed that miR-17 is an E2F1 regulator. Fur-
thermore, Cloonan et al. (2008) have shown that miR-17-5p acts
speciﬁcally on the transition from G1/S cell cycle phases, interfering
with more than 20 genes.
Taken together, these results suggest that a possible mecha-
nism for Lippia oils growth inhibition might be through reversion
of expression of miRNAs regulating cell cycle inhibitors.
In conclusion, the four essential oils tested in this study showed
an antiproliferative effect on CT26.WT colon cancer cells that lead
to a cell cycle arrest on G0/G1 or G2/M phases. This effect might be
attributed to the compounds of those essential oils whose mech-
anism of action potentially involves differential expression of key
oncogenic miRNAs.
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Fig. 2. Heatmap of differentially expressed microRNAs in CT26.WT cell line after
treatment with Lippia oils. CT26.WT cells were treated with 100 mg/ml  of L. alba
(Alb), L. sidoides (Sid), L. rotundifolia (Rot) and L. lacunosa (Lac) essential oils for 12 h.
A  pool of triplicates of each treatment was subjected to microRNAs analysis by real-
time PCR test using a panel of 95 cancer-related microRNA. The Ct values obtained
were normalized from the U6 transcribed and analyzed by the REST software (sig-
niﬁcance level p < 0.05). The values of fold change obtained above 1, referred to
u
a
E
P
t
t
cells. Fundam. Clin. Pharmacol. 23, 549–556.p-regulated microRNAs, were divided into two groups as well as those between 0
nd  1 corresponding to the down-regulated microRNA.
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